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Abstract
Background:  The limited circulation of many of the agents that are likely to be used in a
bioterrorism attack precludes the ready availability of positive controls. This means that only
specialized laboratories can screen for the presence of these agents by nucleic amplification assays.
Calibrated controls are also necessary for quantitative measurements. Primers and probes to be
used in both conventional and real-time PCR assays were designed for the detection of agents likely
to be used by a bioterrorist. Three plasmids, each of which contains 4 to 6 specific sequences from
agents on the CDC Category A and B list (excluding RNA viruses) were constructed. Two plasmids
incorporate the sequences of Category A and B agents, respectively. The third plasmid
incorporates sequences from Variola major and organisms that cause rash-like illnesses that may
be clinically confused with smallpox. An "exogenic sequence", introducing a NotI restriction site was
incorporated in the native sequences of the bioterrorism agents inserted in plasmids. The designed
molecular system for detection of bioterrorism agents was tested on each of these agents (except
Monkeypox virus, Smallpox virus and 2 Burkholderia species for which no native DNA was available)
and a collection of 50 isolates of C. burnetii using constructed plasmids as positive controls.
Results: Designed primers and probes allowed molecular detection, in either single or multiplex
assays, of agent-specific targets with analytical sensitivities of between 1 and 100 DNA copies. The
plasmids could be used as positive controls. False-positive results due to contamination by the
positive control were easily detected by sequencing and eliminated by digestion with NotI.
Conclusion: Plasmid A and B can be used as positive controls in molecular assays for the detection
of bioterrorism agents in clinical specimens or environmental samples. Plasmid C can be used as a
positive control in differentiation of vesicular rashes. It is also possible to avoid or to ensure
immediate detection of false positive results due to contamination by positive controls using these
plasmids. These plasmids and the corresponding primers and probes are immediately available for
all clinical microbiology laboratories provided they have molecular amplification equipment.
Background
Following press reports on a case of inhalation anthrax in
Florida, USA, on October 4, 2001 [1], the bioterrorism
threat became more obvious, and health authorities in the
different countries have intensified preparedness and
response programs. The Centers for Disease Control and
Prevention (CDC) in the USA has listed the potential
agents of bioterrorism (AB) for public health
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preparedness efforts. They have been classified by order of
priority as categories A and B (Table 1). Detection of these
agents will have to be performed from various specimens,
including environmental samples (such as powders) and
clinical samples of patients with symptoms compatible
with infection caused by AB. In fact, 120 reference labora-
tories in the USA and Canada have the capacity to identify
most of AB [2]. Suspect bacterial or viral isolates obtained
in culture must also be identified. Molecular assays for the
detection and identification of infectious agents can be
performed in clinical microbiology laboratories that have
specific equipment and facilities.
However, several problems limit a large diffusion of
molecular techniques for detection of AB: (i) due to safety
regulations, it is difficult to obtain nucleic acids of poten-
tial AB to calibrate the techniques and serve as positive
controls, (ii) several microorganisms would have to be
tested simultaneously by using different controls, (iii) in
some instance, such as for detection of anthrax spores,
quantification would be useful as the size of spore inocu-
lum has been demonstrated to be related with lethal dose
in non human primates [3], (iv) false positive results due
to contamination from positive controls should be
avoided, (v) levels of equipments and methodologies
used currently in clinical microbiology laboratories are
highly variable. Currently, commercially available rapid
tests are limited for the detection of B. anthracis, Brucella
sp., Francisella tularensis and Yersinia pestis [4].
In this study, we propose a new strategy for the prepara-
tion of positive controls to overcome these problems. We
designed 2 plasmids (CatA and CatB) that contain 4 and
6 AB sequences to serve as positive controls. We also
designed primers and probes to detect DNA of these
agents. We designed a plasmid (CatVEF) to detect variola
and other agents that can cause vesicular rash and mim-
icking it. It contains sequences of Herpes viruses, Vari-
cella-zoster virus, Rickettsia akari (the agent of
rickettsialpox) and broad-spectrum orthopox viral
sequences. We modified the native sequences by replace-
ment of 8 nucleotides with a 20 nucleotide exogenic
sequence that contains a NotI site. This modification
allows NotI pre-digestion of the sample to avoid contam-
ination by plasmid DNA. Moreover, amplified DNA from
the control can be differentiated from the natural agent by
(i) NotI digestion, (ii) sequencing and (iii) analysis of
melting curves. NotI pre-digestion of the extracted DNA
eliminated plasmid DNA contaminating amplicons.
Choice of targeted DNA, validation of constructed plas-
mids, tests for sensitivity and specificity of the chosen tar-
gets, quantification assays and ability to differentiate
amplified plasmid DNA from native DNA by using
Table 1: Genes and specific primers used for amplification of Bioterrorism agents. Bioterrorism agents are classified according to CDC 
recommendations. Their presence in the 3 constructed plasmids is given.
Agent Priority 
Level
Targeted gene Plasmid Genbank 
access n°
Forward primer Reverse primer
Bacteria
Bacillus anthracis A pag CatA AF065404 5'-AGGCTCGAACTGGAGTGAA-3' 5'-CCGCCTTTCTACCAGATTT-3'
Yersinia pestis A pla CatA M27820 5'-ATGGAGCTTATACCGGAAAC-3' 5'-GCGATACTGGCCTGCAAG-3'
Francisella 
tularensis
A fopA CatA AF097542 5'-TAATAATTTCATTGCTCCTTTTG-3' 5'-TTCTATCTTGAGGACCCCAA-3'
Brucella spp. B omp19 CatB L27997 5'-CCGGTGAACTGGCTAATCT-3' 5'-TGAAGAATAGAGCGAGGCAA-3'
Burkholderia 
mallei
B fliC CatB AF11790 5'-GACGCTGGCGCTGTCGA-3' 5'-CGGCTTGTTGACCGCGTT-3'
B. pseudomallei B CatB U82287
Chlamydia psittaci B ompA CatB AF269265 5'-ATTGCTTCGATTCAGATCAAC-3' 5'-ACCAGTGATTGACCATTTGT-3'
Coxiella burnetii B sodB CatB M74242 5'-CTTTTTACCGACTCCGCAAA-3' 5'-ACGAGCGTTGACAGTGCTT-3'
Rickettsia 
prowazekii
B ompB CatB AF161079 5'-GCTCTTATGAATAATAATGCTC-3' 5'-TGTTGTAACGCAGCATTAACA-3'
Rickettsia rickettsii B ompA CatB U83451 5'-TTTGGTGGAGCTCATAAGTTA-3' 5'-GTACTATATTTGTTGTATTAAAAG-3'
Rickettsia akari - ompB CatVEF AF123707 5'-TTGGTGGGAATAATTGTAATGT-3' 5'-TGCAGCAAAATTGAATTCTG-3'
Viruses
Variola virus A Hemagglutinin CatA, CatVEF AF377893 5'-GACKTCSGGACCAATTACTA-3' 5'-TTGATTTAGTAGTGACAATTTCA-3'
Monkeypox virus - Hemagglutinin CatVEF AF375114 5'-AAAGTAGATTATGAAGAATACTC-3' 5'-CAGAAATAGTTTCGACAATTTCA-3'
Orthopoxvirus - Hemagglutinin CatVEF AF377892 5'-ACCAAGGATAAARTATCWTACG-3' 5'-ATAYATAAGTACCCGGCATCT-3'
Varicella-
zostervirus
- IE 62 transactivator CatVEF X04370 5'-GGTTAAACGTTTGAATCCATC-3' 5'-CAGCAGACTTTCTCGAACG-3'
Herpes simplex 
virus 1 and 2
- DNA polymerase CatVEF X14112 5'-CCGACCCGGAGAGGGAC-3' 5'-CCAGGCGCTTGTTGGTGT-3'BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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different DNA amplification techniques, including multi-
plex assay, are herein described.
Results
No viable organisms could be recovered using the Chelex
procedure. No colonies were obtained from treated B.
anthracis spore suspension.
Targeted genes, sequences, probes and primers are sum-
marized in Table 1, 2 and additional file 1. Targeted
sequences of the 3 plasmids demonstrated that they were
identical to the in silico predicted sequences. The specific
sequences of plasmids CatA, CatB and CatVEF have been
deposited in Genbank database under AY333963,
AY333965, and AY333966 accession numbers, respec-
tively. The construction of CatA is represented in Figures 1
and 2. E. coli strains harboring these plasmids are depos-
ited at the CNCM collection (CNCM, Paris, France) under
numbers I3087, I3088 and I3089, respectively. The
sequences of the plasmids were verified after they were
sent back by the CNCM for verification in our laboratory.
Thirteen viral and bacterial targeted agents were detected
by using the primers and probes developed in this study
using standard PCR, Taq Man and Light Cycler real-time
PCRs (Table 1 and 2). Four agents were not available
(Monkeypox, Smallpox virus and 2 Burkholderia species).
Only the specific primers with the corresponding DNA
gave positive results. Multiplex real-time PCR results were
identical. The 15 targeted plasmid sequences were
detected using the same primers. Amplicons were differ-
entiated from the native DNA by aspect of melting curves
and sequencing of the amplifiates (Figure 3, additional
file 2). All 50 C. burnetii strains were detected using the
same procedures.
Respective sensitivity of the 15 pairs of primers towards
the 17 target DNA sequences was evaluated by ten-fold
and/or two-fold serial dilutions of a plasmid DNA master
solution containing one femtomole/µL of DNA, on a
Light Cycler platform with SYBRGreen standard protocol.
The results are presented in Table 3. Briefly, sensitivities
ranged 5–50 molecules for the 3 plasmids, except for F.
tularensis  (500 molecules) and R. rickettsii (100
molecules).
Schematic representation of plasmid CatA Figure 1
Schematic representation of plasmid CatA This plasmid contains specific sequences of category A agents of bioterror-
ism (green/white/pink), exogenic sequences (yellow/blue) with inserted NotI site (blue). Primers (green) have been designed to 
amplifiate agent specific sequences and probes (pink) to detect specifically each sequences.
Seq1 smallpox virus Seq2 B. anthracis Seq3 F. tularensis Seq4 Y. pestis
Cat.A Plasmid
Enzyme stabilization sequence 
Enzyme restriction site or residue
after restriction
Primers hybridization site
Agent specific sequence
Probe hybridization site
Exogenic sequence
NotI restriction siteBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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However, sensitivities on native DNA from these species
were < 5 and 50 molecules respectively. Combined quan-
tification of the bacterial suspension and its plasmid-
derived DNA permitted to estimate that a single E. coli
contained 100–200 copies of the plasmid and therefore
100–200 molecules of the target sequence. Quantifying
the number of AB by comparison towards an E. coli cul-
ture will permit to bypass the plasmid extraction proce-
dure that may be cumbersome to perform in an
Construction of DNA control plasmid designed for the 4 CDC Category A DNA agents (Smallpox virus [seq1], Bacillus anthra- cis [seq2], Francisella tularensis [seq3], and Yersinia pestis [seq4]) Figure 2
Construction of DNA control plasmid designed for the 4 CDC Category A DNA agents (Smallpox virus [seq1], 
Bacillus anthracis [seq2], Francisella tularensis [seq3], and Yersinia pestis [seq4]). Assembling of the smallpox virus 
and B. anthracis sequences is presented as an example. Successive steps are indicated by framed numbers. 1, PCR amplification 
of the two matrix sequences by primers consisting of the stabilization and the restriction site sequences (italics). PCR reactions 
were carried out in a volume of 50 µl that included 10 mM Tris-HCl [pH 9.0], 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100, 
200 µM each dNTP, 0.4 µM of each oligonucleotide primer, 0.4 µM of the single stranded DNA, and 1.5 U of Taq DNA 
polymerase (Invitrogen, Cergy-Pontoise, France). The thermocycler (Biometra, Göttingen, Germany) profile was 5 min at 
95°C, followed by 35 cycles of 30 sec at 95°C, 30 sec at 55°C, and 1 min at 72°C, and terminated by a final extension for 7 min 
at 72°C. PCR products were electrophorezed in 3% TAE-agarose gel containing ethidium bromide and visualized under UV 
transillumination. Column purification of the PCR products. PCR products of the expected size were column-purified by using 
the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, and eluted in 50 µl 
of RNase free distillated water. When two bands or more were observed by gel analysis, the band of expected size was 
excised from the gel and purified by glass milk extraction with the GenClean III Kit (Q-Bio-Gene, Carlsbad CA, USA). 2, assem-
blage was conducted by pair, seq1 with seq2 (resulting in seq1-2). Equal volumes (10 µl) of purified seq1- and seq2-dsDNA 
were incubated at 37°C in the presence of Sac I. Sac I site is located at the 3' and 5' ends of seq1 and seq2, respectively. 3, the 
reaction product was column purified using the protocol aforementioned to discard the 15-nt DNA fragments corresponding 
to the 5' and 3' ends to avoid their re-ligation to their respective complementary sequences at step 5. 4, Overnight incubation 
at 4°C in the presence of T4 DNA ligase. Ten µl of the reaction was incubated with T4 DNA ligase (Roche, Basel, Switzerland) 
according to the manufaturer's instructions. 5, PCR amplification by using the external primers (italics) was performed accord-
ing to the protocol described at step 1. Then column purification using the protocol detailed at step 2 of the resulting PCR 
product. At this step the seq1-2 PCR product may be cloned into PGEM-T for storage. The same procedure was performed 
for seq3 and seq4. Ultimately, seq1-2 and seq3-4 were assembled by using the same protocol (sections 1–9). The final product 
cloned into PGEM-T plasmid includes seq1-2-3-4 flanked by the two Sseq and restriction sites.
Purified PCR product including variola virus specific sequences Purified PCR product including B. anthracis specific sequences
1 hr incubation @ 37°C in the presence of Sac I
Column purification to discard the small DNA fragments remnant from
the restriction reaction
Overnight incubation in the presence of T4 DNA ligase @ 4°C
Seq1 [variola] Seq2 [B. anthracis]
Seq1 [variola] Seq2 [B. anthracis]
Seq1 [variola] Seq2 [B. anthracis]
Sac I
site
Sac I
site
1
2
3
4
5BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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emergency context. Multiplex and standard PCR protocol
displayed similar sensitivities with both native and plas-
mid DNA.
We tested DNA from BA, their genetically close relatives
and common agents in clinical microbiology. None of the
PCR tests carried out using the 15 pairs of primers against
DNA from these 45 tested agents generated unspecific
amplicons. None of the DNA extracted from the non
anthracis Bacillus sp. generated amplicons.
No amplicons were obtained from the plasmid DNA sus-
pension digested by NotI, whereas this procedure did not
inhibit amplification of the native DNA (Figure 3). Ampli-
cons from plasmid DNA were digested by NotI but not
those from native DNA (Figure 3).
Discussion
The CDC has organized detection and diagnosis of bio-
logical warfare agents on laboratory testing abilities and
facilities by classifying laboratories according to their
core-testing capacities [5,6]. Recent developments of com-
mercial kits for detection and quantification of infectious
agents, such as Chlamydia trachomatis or HIV [7,8], means
that molecular detection techniques are increasingly
being used in clinical microbiology laboratories. How-
ever, control DNA is necessary for ensuring that there are
no inhibitors in the specimens and that the assay is work-
ing properly. It is obvious that distribution of AB to all
laboratories is not considered. As a matter of fact, this
inability to obtain DNA from these agents, make it
impossible to test our primers on the native DNA from
variola virus, Monkey pox virus, B. mallei and  B.
pseudomallei.
In this study, we have constructed plasmids containing
sequences of different pathogens. This allows limitation
of the number of controls to be used. We also introduced
a very simple method of decontamination using Chelex
[9,10] that kills B. anthracis spores. It can be applied to all
tested specimens. We also designed primers to amplify
DNA from either plasmids or AB and demonstrated that
they ensured AB detection with high sensitivity and specif-
icity. Primarily, the specificity was checked "in silico" and
then with a collection of potentially confounding organ-
isms. Multiplex-PCR assay can be performed using these
primers and controls. This enables us to detect all AB of a
given class (class A and B). The procedure was also
demonstrated to be efficient in real-time PCR. Moreover,
false positive amplicons resulting from carryover or from
preceding amplification of the positive control are easily
recognized. As for F. tularensis and R. rickettsii, the number
of detected copies from the plasmid DNA was higher than
for the other AB. This was not correlated with a lower sen-
sitivity on native DNA.
The strategy we propose may allow detection of AB by all
laboratories with molecular biology facilities. The CatA
and CatB plasmids could be used for the detection of AB
from suspect powders and human samples as in the case
of suspected pneumonia (including C. burnetii, C. psittaci,
Burkholderia, B. anthracis, Y. pestis, R. prowazekii and F. tula-
rensis). The procedure also allows identification of iso-
lated micro-organism suspected of being an AB.
The CatVEF plasmid is to be used for the detection of AB
from humans who are suffering from vesicular eruption
resembling that of smallpox. It combines DNA from
agents that can be clinically confounding. Few infectious
agents cause a vesicular rash. The most common
Table 2: Sequence of probes used for hybridization in real time PCR assays
Targeted agent Probe sequence
Variola virus 5'-AAGATCATACAGTCACAGACACTGT-3'
Bacillus anthracis 5'-TACCGCAAATTCAAGAAACAACTGC-3'
Francisella tularensis 5'-TTGCAAATACTTATAGCGCTTTGACT-3'
Yersinia pestis 5'-AAGGAGTGCGGGTAATAGGTTATAA-3'
Burkholderia mallei; B. pseudomallei 5'-AACCAGCGCGCTGTCCGCGAC-3'
Chlamydia psittaci 5'-ATGAAATCTAGAAAATCTTGTGGTGTA-3'
Coxiella burnetii 5'-ATCATTTCGGCTCGGGATGGGC-3'
Brucella spp. 5'-AATGGCAAGCAACTCGTCCTTTAC-3'
Rickettsia prowazekii 5'-TGGTTCTATTCAGTTAGATGGGAGT-3'
Rickettsia rickettsii 5'-TATATTGTTCAAAGGAGCGGGAGAT-3'
Monkeypox virus 5'-TTGATTGTAAATACAGATAGTGAATCG-3'
Orthopoxvirus 5'-TCCATACGATGATCTAGTTACAACTA-3'
Varicella-zoster virus 5'-ATGCCACCTTTACAGTTGGAGGAA-3'
Herpes simplex virus 1 and 2 5'-ACCGCCGAACTGAGCAGACACC-3'
Rickettsia akari 5'-ACGTCTTATGGCAGGAACAAATTTAG-3'BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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differential diagnosis is the infection by Varicella-zoster
virus. Generalized herpes virus infection may also be diffi-
cult to differentiate. Moreover, after the anthrax alert in
the USA began at the autumn 2001, the number of cases
of diagnosed rickettsialpox, a rare disease caused by R.
akari, suddenly increased as physicians confronted by
patients with vesicular rash or skin eschar wanted to con-
firm whether it was rickettsialpox or smallpox [11].
Molecular detection and identification of true and false positives using plasmid CatA as positive control Figure 3
Molecular detection and identification of true and false positives using plasmid CatA as positive control. 3a. 
NotI predigestion of CatA plasmid DNA. A, B, C, D correspond to Not I digested-CatA plasmid DNA (overnight digestion with 
10 U followed by an 1-hour digestion with another 10 U) respectively PCR amplified with Y. pestis, F. tularensis, B. anthracis, and 
smallpox virus oligonucleotide primers. E, F, G, H correspond to the same DNA samples which have not been digested by NotI. 
3b. Discrimination of Y. pestis amplicons by NotI post-PCR digestion in a 3% agarose gel. lane I, NotI post-PCR digestion of 
amplicon from Y. pestis native DNA (101 bp); lane J, amplicon from CatA plasmid DNA (113 bp); lane K, NotI post-PCR diges-
tion of amplicon from CatA plasmid DNA (digestion result in 2 products of 76 bp and 37 bp, respectively; only the 76 bp prod-
uct is seen). 3c. Melting curves obtained from SYBR Green Light Cycler reactions. Curve A was obtained with CatA plasmid 
DNA and Y. pestis primers; curve B was obtained with Y. pestis DNA amplified with Y. pestis specific primers; curve C was 
obtained with Y. pestis DNA amplified in a multiplex reaction including the 8 primers specific for the category A agents (Y. pes-
tis, F. tularensis, B. anthracis, smallpox virus). The melting temperature observed with A is 82.65 whereas it is 81.97 with native 
Y. pestis DNA (curves B and C).
ABC
A
B
C
a b
c
b
DE F G H I J K
113 bpBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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Another outbreak of vesicular rashes, resembling small-
pox in the USA, was in fact the cases of monkeypox infec-
tions [12]. Finally, with increasing diffusion of
vaccination campaign, accidental vaccinia will occur [13],
challenging the diagnosis of smallpox. Differential labo-
ratory diagnosis of such cases has been tentatively done by
using in situ hybridization on cutaneous biopsies [14], but
the plasmid CatVEF we propose may also reveal useful.
We believe that our strategy of multiple target plasmids
brings two major improvements. It allows to perform
quantitative detection that can be of importance, in the
case of B. anthracis spores, by helping to evaluate the risk
of pulmonary anthrax. It overcomes problems due to PCR
contamination by positive control. Discrimination of
plasmid DNA from native DNA may be insured a posteriori
by observation of different melting curves, sequences or
NotI digestion. Such a strategy of target modification for
use as a control was previously described for detection of
B. anthracis by modification of the size of the amplified
fragment [15]. However, our strategy using incorporation
of a restriction enzyme site represents an improvement,
allowing to perform NotI pre-digestion of the sample. In
that case, false positive results due to contamination from
previous experiences using the control are avoided.
Contaminations by the DNA of native AB may be avoided
by incorporation in PCR mix of dUTP rather than that of
dTTP and pre-treatment of samples by Uracil N-glycosy-
lase [16]. A combined pre-treatment with NotI would
allow to work with an un-contaminable PCR procedure.
Conclusions
To our knowledge, we report the first construction of plas-
mids to be used as positive controls in amplification
reactions for AB. It is also possible to avoid or to ensure
immediate detection of false positive results due to con-
tamination by positive controls using these plasmids.
These plasmids and the corresponding primers and
probes for detection of AB are immediately available for
all clinical microbiology laboratories provided they have
molecular amplification equipment. However, before
routine use, primers and probes will have to be exten-
sively studied on collections of the different targeted path-
ogens, as we did it on C. burnetii, the sole agent for which
we have a significant number of isolates. Due to the
increasing availability of complete genome sequences, the
primers and the target genes described in this study can be
changed to others in order to propose different associa-
tions of genes or pathogens.
Methods
For B. anthracis and Y. pestis, previously proposed target
genes were used [17,18]. For other agents, we selected
genes that were sequenced in several isolates, to ensure
that they were conserved in the species. Sequences were
aligned using CLUSTALW software at the PBIL http://
npsa-pbil.ibcp.fr. Primers, chosen in conserved areas,
were designed manually or by using the primer design
tool of CyberGene AB http://www.cybergene.se in order
to design primers with a Tm of approximately 58° C and
a G + C content of less than 50%. Target sequences (Table
1) were compared to the Genbank database using Blastn
software http://www.ncbi.nlm.nih.gov/BLAST/ in order
Table 3: Sensitivity of the detection tests performed onto the Light Cycler platform. For Smallpox virus, Monkey pox virus and 
Burkholderia species, native DNA was not available. For C. psittaci and Varicella-zoster virus titrated micro-organisms were not available.
Plasmid Microorganism Number of molecules detected
Plasmid Native (strain)
CatA Smallpox virus 5N A
CatA Y. pestis 55  ( K i m 5 )
CatA B. anthracis 5 5 (Sneath D455)
CatA F. tularensis 500 5 (URFTMUE1)
CatB Brucella sp. 50 50 (B. melitensis B115)
CatB R. prowazeckii 50 100 (Brein l)
CatB R. rickettsii 100 50 (VR 891)
CatB B. mallei/pseudomallei 50 NA
CatB C. burnetii 5 100 (Nine Mile)
CatB C. psitacci 50 NA
CatVEF Smallpox virus 5N A
CatVEF Monkeypoxvirus 5N A
CatVEF Orthopoxvirus 5 10 (ectromelia TC8)
CatVEF Varicella-zoster virus 5N A
CatVEF Herpesvirus 1/2 5 10 (MA1)
CatVEF R. akari 55 0  ( K a p l a n )BMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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to ensure in silico specificity. The fixed cut-off for in silico
target sequence similarity was < 25% for any other
sequence in any other genera of the GenBank database.
Among members of the same genus this cut-off was
<75%. Exceptions were R. rickettsii for which similarity
with closest relative Rickettsia mongolotimonae was 94%
and R. prowazekii for which similarity with closest relative
Rickettsia typhi was 90%.
The sequences were separately synthesized by an oligonu-
cleotide manufacturer (Eurogentec, Seraing, Belgium).
Each sequence was specific to one agent with exceptions
of B. pseudomallei, which was designed to also recognize B.
mallei, and Brucella which was designed to recognize all
Brucella species. The sequences (129 to 155 nt long) were
organized in a similar manner for all constructions
(Figures 1 and 2): (i) an ATGCATGCATGC sequence to
ensure optimal efficacy of the enzyme during the restric-
tion step (subsequently reported as stabilization sequence
[Sseq]), (ii) the 6-nt sequence was specific for the defined
restriction enzyme, (iii) the sequence of the agent to be
detected which include the sequence of the specific prim-
ers at both extremities, (iv) the positive control exogenic
sequence ATTATA-GCGGCCGC-TTATTA that includes the
Not I site (in bold), (v) a second 6-nt sequence was spe-
cific for a restriction enzyme that is distinct from that
aforementioned, (vi) the same 12-nt Sseq. Accordingly, all
synthetic sequences contain 56 invariable nucleotides.
Three plasmids were constructed such as CatA for category
A agents, CatB for category B agents and CatVEF for vesic-
ular eruptive fever (Tables 1 and additional file 1).
Construction of DNA control plasmid designed for the 4
CDC Category A DNA agents (Smallpox virus [seq1],
Bacillus anthracis [seq2], Francisella tularensis [seq3], and
Yersinia pestis [seq4]) is presented as an example (Figure
1).
Once the four single stranded DNA (ssDNA) sequences
were synthesized by the manufacturer, they were assem-
bled as a single double-stranded DNA (dsDNA) fragment
to be subsequently cloned into the PGEM-T plasmid
(PGEM-T Easy Vector System I kit, Promega France SARL,
Charbonnieres-les-Bains, France). The sequential steps
were as follows (see Figure 2):
1. PCR amplification of each of the 4 single stranded DNA
sequences by using primers consisting of the stabilization
and the restriction site sequences (italics in additional file
1). PCR reactions were carried out in a volume of 50 µl
that included 10 mM Tris-HCl [pH 9.0], 1.5 mM MgCl2,
50 mM KCl, 0.1% Triton X-100, 200 µM each dNTP, 0.4
µM of each oligonucleotide primer, 0.4 µM of the single
stranded DNA, and 1.5 U of Taq DNA polymerase (Invit-
rogen, Cergy-Pontoise, France). The thermocycler (Biom-
etra, Göttingen, Germany) profile was 5 min at 95°C,
followed by 35 cycles of 30 sec at 95°C, 30 sec at 55°C,
and 1 min at 72°C, and terminated by a final extension
for 7 min at 72°C. PCR products were electrophorezed in
3% TAE-agarose gel containing ethidium bromide and
visualized under UV transillumination.
2. Column purification of the PCR products. PCR prod-
ucts of the expected size were column-purified by using
the QIAquick PCR Purification Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer's instructions, and
eluted in 50 µl of RNase free distillated water. When two
bands or more were observed by gel analysis, the band of
expected size was excised from the gel and purified by
glass milk extraction with the GenClean III Kit (Q-Bio-
Gene, Carlsbad CA, USA).
3. Assemblage was conducted by pair, seq1 with seq2
(resulting in seq1-2), seq3 with seq4 (resulting in seq3-4);
then seq1-2 with seq-4 (resulting in seq1-2-3-4).
4. Equal volumes (10 µl) of purified seq1- and seq2-
dsDNA were incubated at 37°C in the presence of Sac I.
Sac I site is located at the 3' and 5' ends of seq1 and seq2,
respectively.
5. The reaction product was column purified using the
protocol aforementioned to discard the 15-nt DNA frag-
ments corresponding to the 5' and 3' ends to avoid their
re-ligation to their respective complementary sequences at
step 5.
6. Overnight incubation at 4°C in the presence of T4 DNA
ligase. Ten µl of the reaction was incubated with T4 DNA
ligase (Roche, Basel, Switzerland) according to the manu-
faturer's instructions.
7. PCR amplification by using the external primers (italics
in additional file 1) was performed according to the pro-
tocol described in section 1.
8. Column purification using the protocol detailed in sec-
tion 2 of the resulting PCR product. At this step the seq1-
2 PCR product may be cloned into PGEM-T for storage.
9. The same procedure was performed for seq3 and seq4
Ultimately, seq1-2 and seq-4 were assembled by using the
same protocol (sections 1–9). The final product cloned
into PGEM-T plasmid includes seq1-2-3-4 flanked by the
two Sseq and restriction sites.
Once the first assembled double stranded DNA was
obtained, it was cloned into PGEM-T plasmid and
sequenced to verify sequence accuracy with primersBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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consisting of the stabilization and the restriction site
sequences (italics in additional file 1). Sequencing of each
assembled DNA was performed to assess sequence
accuracy, and clones that were 100% identical to the
reference sequence were used for further assembling. At
the end, the complete assembled plasmid was sequenced
by using primers located on the PGEM-T plasmid (M13
primers) to verify its 100% identity with the original
sequences.
All DNA extractions were performed using Chelex resin
under previously described conditions [9,10]. DNA solu-
tions were buffered with 10X PCR buffer without MgCl2 to
get a final concentration of 0.5X, and stored at -20°C. The
Chelex extraction procedure was additionally tested onto
B. anthracis spores in order to verify that it ensure spore
killing. Briefly, a heavy suspension of a 96 h agar culture
of B. anthracis in sterile PBS was prepared. Ten µl of this
suspension was deposited on a slide and stained by Wirtz-
Conlin spore staining [19]. Spores, colored in green, were
counted. The suspension was then adjusted to a spore
concentration of 107/ml. A 100 µl aliquot was then sub-
jected to Chelex extraction and inoculated onto sheep
blood agar plate to test growth of B. anthracis.
Amplification conditions were as follows: (I) Standard
PCRs were carried out under a classic 35 cycle-protocol
with hybridization at 55°C (detailed in Plasmid assem-
bly, section 1); (II) Real-time PCR carried out on the ABI
7000 platform used the protocols recommended by the
manufacturer. Briefly, 10 µl of DNA solution was com-
bined with 50 pmol of each primer and 10 pmol of the
FAM- and TAMRA-labeled probe (Table 2) in 50-µl total
reaction volume by using the TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems, Roche, USA). The samples
were subjected to 40 cycles of amplification in an ABI
Prism 7000 or 7700 Sequence Detection System instru-
ment (PE Applied Biosystems) according to the manufac-
turer's protocol for TaqMan assay cycling conditions. The
rate of TaqMan assay positivity was calculated by using the
99.9% confidence level settings in the PE 7000 or 7700
Sequence Detection System software; (III) Real-time PCR
carried out on the Light Cycler platform used the
SYBRGreen protocols recommended by the manufacturer.
Briefly, 1 µl of tenfold serial dilution of DNA solutions
was combined with 50 pmol of each primer in a 20-µl
total reaction volume by using the LightCycler FastStart
DNA Master SYBR Green I Kit (Roche Applied Science).
The samples were subjected to 40 cycles of amplification
in a LightCycler (Roche) with a 58°C-hybridization step.
Evaluation of the sensitivity of the Light Cycler detection
for each of the 15 systems (Tables 1 and 2) were done by
testing serial tenfold dilutions of the plasmid and quanti-
fied native DNA. NotI digestion of the PCR products was
performed for 1 hr at 37°C in a 20 µl volume and results
were observed after 3% agarose gel electrophoresis under
UV transillumination.
The specificity of the 15 pairs of primers was evaluated by
(i) cross-amplification of the 13 cat.A/B and VEF agents of
which sequences have been incorporated into the plas-
mids, (ii) tentative amplification of closely related bacte-
ria or viruses and (iii) tentative amplification of bacteria
and viruses frequently isolated/detected in microbiology
laboratories. Selected agents were:
(i) the 13 bacteria and viruses to be detected: C. burnetii,
F. tularensis, R. rickettsi, R. akari, R. prowazeckii, Y. pestis, B.
anthracis, C. psitacci, B. melitensis, vaccinia virus, varicella-
zoster virus and herpesvirus 1 and 2.
(ii) a batch of 50 randomly selected C. burnetii isolates
from our collection.
(iii) 5 closely related microorganisms: Rickettsia typhi,
Rickettsia conorii, Yersinia enterocolitica, Bacillus cereus and
Bacillus thurigiensis.
(iv) 28 human pathogens frequently isolated in microbi-
ology laboratories: Corynebacterium ANF group, Nocardia
asteroides, Shigella flexneri, Mycobacterium avium, Campylo-
bacter jejuni, Streptococcus agalactiae, streptococcus pyogenes,
Pseudomonas paucimobilis, Actinomyces viscosus, Shigella son-
nei, Streptococcus bovis, Burkholderia cepacia, Listeria monocy-
togenes,  Clostridium perfringens,  Actinomyces meyerii,
Fusobacterium nucleatum,  Escherichia coli,  Staphylococcus
aureus,  Propionibacterium acnes,  Haemophilus influenzae,
Bacteroides fragilis, Salmonella enterica Typhi, Kingella kin-
gae, Enterobacter aerogenes, Corynebacterium striatum, Bar-
tonella quintana,  Legionella pneumophila and  Neisseria
meningitidis.
(v) a batch of 12 non anthracis Bacillus sp. isolated in our
laboratory from suspect powders [20]
Both sensitivity and quantification tests were performed
by using real-time PCR procedure on a Light Cycler plat-
form (Roche) with the SYBRGreen standard protocol rec-
ommended by the manufacturer in a 20 µl final volume.
Hybridization temperature was set at 58°C for all primers.
The three plasmid-harboring E. coli were grown overnight
at 37°C under shaking conditions in 10 mL of LB medium
containing 100 µg/mL of ampicillin; the cultures were
quantified spectrophotometrically and were adjusted to
108 bacteria/mL. For each plasmid, three 3-mL aliquots
were independently pelleted by centrifugation. Superna-
tant was discarded and the pellet was used to extract plas-
mid DNA by a standard Miniprep procedure (QiaPrep
Spin Miniprep Kit, Qiagen, Hilden, Germany) accordingBMC Microbiology 2004, 4 http://www.biomedcentral.com/1471-2180/4/21
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to the manufacturer's recommendations. This plasmid
DNA was spectrophotometrically measured at 260/280
nm, and was adjusted by dilution to a concentration of 1
femtomol/µL constituting the stock solution. The latter
was subsequently serially diluted at tenfold, and 1 µL of
each dilution was tested by Lightcycler real-time PCR.
Final adjustment of the minimal number of molecules
detectable by each pair of primers was determined by test-
ing the series of twofold dilutions. Experiments were con-
ducted in triplicate. Combined quantification of the
bacterial suspension and its plasmid-derived DNA permit-
ted to estimate the number of plasmid copies harbored by
a single bacteria. Sensitivity of the technique to detect AB
was determined by testing titrated suspensions of these
agents. Titration of agar growing bacteria was performed
by macrobroth dilution method [21]. Titration of purified
strict intracellular bacteria was performed by flow cytom-
etry counting [22]. Herpes simplex virus 1 was titrated by
cell culture infectious dose 90 on Vero cells [23]. Orthopox-
virus was titrated by electronic microscopy negative stain-
ing counting.
The suitability of multiplex protocols was evaluated with
primers and probes corresponding to each of the three
plasmids, respectively. Briefly, serial dilutions of each
plasmid and corresponding native DNA were tested in
reactions including (i) all primers and probes against plas-
mid DNA, (ii) all primers and probes against native DNA,
(iii) all primers and the specific probe of each agent
against plasmid DNA and (iv) the two primers and the
probe specific for one agent against native DNA.
To address the possibility of pursuing the testing even
whether a laboratory contamination has been detected in
previous experiments, we tested the suitability of a decon-
tamination procedure based on NotI treatment of
extracted nucleic acids prior to start the PCR protocol. A
DNA suspension adjusted to a concentration 106 times
higher than the limit detection was prepared for the 4
plasmids. Three test solutions were then either tested
directly after nucleic acid extraction, or submitted to a
one-hour restriction in the presence of NotI at 37°C: they
consisted of (i) plasmid nucleic acid (NA) alone simulat-
ing a laboratory-contaminated negative specimen, (ii)
plasmid NA mixed with native NA simulating a labora-
tory-contaminated positive specimen, (iii) native NA sim-
ulating a true positive specimen.
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